UncategorizedArrowhead inks $2b neurodegeneration deal with Novartis Empower Meds / September 2, 2025
UncategorizedVutrisiran shows long-term benefit in ATTR-CM Phase 3 study – Longevity.Technology Empower Meds / September 2, 2025
UncategorizedWegovy cuts heart attack, stroke and death risk in CVD patients Empower Meds / September 2, 2025
UncategorizedTelomir Pharmaceuticals sees new in vitro evidence supporting Telomir-1 epigenetic potential – Longevity.Technology Empower Meds / September 1, 2025
UncategorizedBanner year for Mesoblast with FDA approval and launch of Ryoncil – Longevity.Technology Empower Meds / September 1, 2025
UncategorizedAlnylam to advance zilebesiran into global phase 3 hypertension study – Longevity.Technology Empower Meds / September 1, 2025
UncategorizedImmortal Dragons backs Frontier Bio in advancing 3D biofabrication – Longevity.Technology Empower Meds / September 1, 2025
UncategorizedProHealth Longevity launches pharmaceutical-grade methylene blue supplement – Longevity.Technology Empower Meds / September 1, 2025
UncategorizedMinovia lands funding to develop mitochondria biomarkers Empower Meds / September 1, 2025
